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Different capsular serotypes of Streptococcus pneumoniae vary markedly in their ability to cause invasive infection, but the rea-
sons why are not known. As immunity to S. pneumoniae infection is highly complement dependent, variations in sensitivity to
complement between S. pneumoniae capsular serotypes could affect invasiveness. We have used 20 capsule-switched variants of
strain TIGR4 to investigate whether differences in the binding of the alternative pathway inhibitor factor H (FH) could be one
mechanism causing variations in complement resistance and invasive potential between capsular serotypes. Flow cytometry as-
says were used to assess complement factor binding and complement-dependent neutrophil association for the TIGR4 capsule-
switched strains. FH binding varied with the serotype and inversely correlated with the results of factor B binding, C3b/iC3b
deposition, and neutrophil association. Differences between strains in FH binding were lost when assays were repeated with
pspCmutant strains, and loss of PspC also reduced differences in C3b/iC3b deposition between strains. Median FH binding was
high in capsule-switchedmutant strains expressing more invasive serotypes, and a principal component analysis demonstrated a
strong correlation between serotype invasiveness, high FH binding, and resistance to complement and neutrophil association.
Further data obtained with 33 clinical strains also demonstrated that FH binding negatively correlated with C3b/iC3b deposition
and that median FH binding was high in strains expressing more invasive serotypes. These data suggest that variations in com-
plement resistance between S. pneumoniae strains and the association of a serotype with invasiveness could be related to capsu-
lar serotype effects on FH binding.
The nasopharyngeal commensal Streptococcus pneumoniae isalso a common bacterial pathogen, responsible for a high pro-
portion of cases of pneumonia, meningitis, and septicemia. The
capsule is the most important S. pneumoniae virulence factor and
is classified into over 90 antigenically distinct capsular serotypes
(1). The biology of S. pneumoniae varies markedly between sero-
types (2–8), and understanding themechanisms causing these dif-
ferences will help identify characteristics required for virulence.
For example, for each episode of carriage in the nasopharynx,
some serotypes of S. pneumoniae aremuchmore likely than others
to cause invasive disease (defined as isolation of S. pneumoniae
from a sterile site, mainly the blood) (5, 6, 8). Epidemiological
studies have used the ratio of cases to carriers to provide estimates
for relative serotype invasiveness, which can be represented as the
number of cases of invasive disease per 100,000 colonization
events (the attack rate) (5) or as case-to-carrier ratios (6, 8). With
some exceptions, the different data sets identify similar sets of
serotypes as being more invasive, but the reasons underpinning
the link between a serotype and invasiveness are poorly under-
stood. Relative serotype invasiveness is of increasing importance
due to the changes in S. pneumoniae serotype ecology following
universal vaccination with conjugated polysaccharide vaccine.
This vaccine has dramatically reduced the prevalence of strains
expressing serotypes included in the vaccine but is associated with
an increase in nonvaccine serotypes in carriage and invasive dis-
ease (9, 10), which is called serotype replacement. To date, sero-
type replacement has been essentially complete in nasopharyngeal
carriage, with the overall S. pneumoniae carriage prevalence in
vaccinated populations about the same as that before vaccination.
However, in children, invasive disease has declined overall, sug-
gesting that the invasiveness of the replacing serotypes is less than
that for the types in the vaccine (9, 11).
The S. pneumoniae capsule can inhibit several aspects of host
immunity, including neutrophil extracellular traps and both com-
plement-dependent and complement-independent neutrophil
phagocytosis (12, 13). Complement is vital for protection against
septicemia (14–16), suggesting that the effect of the capsule on
complement resistance is onemajor reasonwhy the capsule is vital
for the development of invasive disease. Complement resistance
varies markedly between S. pneumoniae strains, and this is related
to both the capsular serotype (2, 3, 17, 18) and other genetic vari-
ation between strains (18, 19). Infection with serotypes that were
resistant to complement resulted in greater bacterial CFU in the
blood in mouse models of sepsis (2, 4), supporting a hypothesis
that resistance to complement-mediated immunity could par-
tially explain differences in invasiveness between serotypes. How-
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ever, serotype-dependent effects on complement-mediated im-
munity have not been correlated to invasive potential for a large
number of serotypes, and the mechanism by which serotype af-
fects complement activity is not known.
S. pneumoniae has evolved a number of mechanisms to evade
complement-mediated immunity, including the binding of the
host inhibitor of the alternative pathway inhibitor factor H (FH)
to the cell wall proteins PspC and PhtD (20, 21). FH binding
prevents formation of the factor B (Bf)-dependent C3b convertase
on the bacterial surface, thereby potentially reducing S. pneu-
moniae opsonization with C3b (20–22). FH also assists degrada-
tion of C3b to iC3b. PspC and PhtD are subcapsular proteins, and
FH binding to S. pneumoniae is inhibited by the capsule (12).
Furthermore, both the accessibility of PspC and the degree of FH
binding varied between a small number of S. pneumoniaemutants
expressing different capsular serotypes on the TIGR4 background
(4, 22). These data demonstrate that the capsular serotype affects
FH binding, supporting the hypothesis that differences in FH
binding could be one mechanism by which the serotype causes
variation between S. pneumoniae strains in resistance to comple-
ment-mediated immunity. Furthermore, high levels of FH bind-
ing could potentially increase the invasive potential of particular S.
pneumoniae serotypes by preventing complement-mediated im-
munity in the blood.
We have therefore investigated the relationship between FH
binding and resistance to complement and opsonophagocytosis
by neutrophils for a large number of capsule-switchedmutants. In
addition, the results of FH binding and resistance to complement
for capsule-switched variants and representative clinical strains
from common serotypes were correlated with data for serotype-
associated invasiveness reported previously by epidemiological
studies.
MATERIALS AND METHODS
Strains and culture conditions. The isogenic capsular transparent-phase
variants of the S. pneumoniae strain TIGR4 used in this study have been
described previously (2, 4, 23, 24). The 33 clinical strains used represent
commonmultilocus sequence type (MLST) clones for 8 serotypes, and all
isolates were obtained from nasopharyngeal cultures of asymptomatic
children or from invasive S. pneumoniae infections in adults and children
and were described by Hyams et al. (19) (kind gifts from Brian Spratt,
Imperial College, and Birgitta Henriques-Normak, Karolinska). PspC
mutants of capsule-switched variants of TIGR4 were created by transfor-
mation using conventional methods with a pspC deletion construct made
by overlap extension PCR as described previously (22). Bacteria were
cultured at 37°C in 5%CO2 on blood agar plates or in Todd-Hewitt broth
supplemented with 0.5% yeast extract (THY) to a mean optical density at
580 nm of 0.41 (standard deviation [SD], 0.02) for the capsule-switched
strains (meanCFU, 1.09 108 perml; SD, 0.09 108) and 0.40 (SD, 0.01)
for the clinical strains (mean CFU, 1.17 108 perml; SD, 0.02 108) and
stored at70°C in10% glycerol as single-use aliquots.
Serum source, flow cytometry, and ELISAs. Pooled human serum
was obtained from unvaccinated normal human volunteers and stored in
single use aliquots at70°C. Capsule-specific antibody titers for clinically
relevant serotypes were measured using standardized enzyme-linked im-
munosorbent assays (ELISAs) with preabsorption with C-polysaccharide
and serotype 22F capsular polysaccharide as described (http://www
.vaccine.uab.edu/ELISA%20Protocol.pdf). Total IgG binding to S. pneu-
moniae (representing both anticapsular and antiprotein antigen activity),
C3b/iC3b deposition, iC3b, FH, and Bf binding to S. pneumoniae after
incubation in 20% serum for 20 min at 37°C were measured using flow
cytometry assays and R-phycoerythrin goat anti-human IgG (Jackson
ImmunoResearch) or fluorescein isothiocyanate (FITC)-conjugated anti-
human C3 or iC3b, anti-FH, or anti-Bf (ICN) as described previously (2,
12, 15, 16, 19). As complement factor binding to S. pneumoniae is often
biphasic with strongly positive and weakly positive populations of bacte-
ria, results are presented as a fluorescence index (FI; percentage of positive
bacteria multiplied by the geometric mean fluorescence index (MFI) in
arbitrary units) (2, 12, 15); this ensures both intensity (geometric mean
MFI) of complement factor binding and the proportion of positive bac-
teria are included in the data analysis. Each strain gave highly consistent
results using stocks from independent THY cultures (correlations for data
from two stocks of the same capsule-switched strain gave an R2 of 0.94 for
C3b/iC3b deposition and 1.0 for FH binding). Neutrophil association (a
measure of phagocytosis) (12) was investigated using flow cytometry to
identify the proportion of fresh human neutrophils (105 per reaction)
associated with 6-carboxyfluorescein succinimidyl ester (FAMSE;Molec-
ular Probes) labeled S. pneumoniae (106 per reaction) after preincubation
in 20% serum for 20 min at 37°C as described previously (2, 12). Neutro-
phil killing assays were performed using freshly isolated human neutro-
phils and bacteria (in a ratio of 800 cells per bacterium) preincubated in
phosphate-buffered saline (PBS) with heat-treated (65°C for 20 min to
neutralize complement activity) or untreated serum as described previ-
ously (12).
Immunogold electron microscopy. Electron microscopy (EM) was
performed using mid-log-phase capsule-switched S. pneumoniae strains
(2) incubated at 37°C for 20 min in serum, a Jeol 1010 transmission elec-
tron microscope (100 kV), and a ruthenium red and London Resin pro-
tocol. C3b/iC3b deposition was detected by an immunogold detection
method using 1/100 FITC goat polyclonal anti-C3 (ICNBiomedicals) and
1/100 immunogold conjugated rabbit anti-goat antibodies as described
previously (12). The numbers of gold particles associated with bacteria
were counted for 10 or more randomly chosen bacteria per strain and
expressed as medians (interquartile ranges [IQRs]).
Statistics. Flow cytometry data between individual strains were ana-
lyzed using one-way analyses of variance (ANOVAs) withDunn’s post hoc
test and presented as standard errors of the means (SEM). Complement
factor binding and phagocytosis data for individual strains were corre-
lated using Spearman’s correlation test for nonparametric data. Immuno-
gold EMdata were compared using a Kruskal-Wallis test withDunn’s post
hoc test and presented as IQRs. Pooled data for serotypes with high or low
attack rates were compared using Mann-Whitney U tests. Log-trans-
formed data from each of the measurements above were used for a prin-
cipal component (PC) analysis. For the PC analysis, variance in comple-
ment component binding and phagocytosis assays between different
serotypes was assessed in R v2.11.1 (www.r-project.org) to obtain scores
for each serotype and loading values for each measurement parameter in
all PCs.
RESULTS
Effects of capsular serotype on binding to complement factors.
To investigate the effect of the capsular serotype on FH binding to
S. pneumoniae independent of other genetic variation between
strains, FH binding to a panel of 20 capsule-switched mutants of
the TIGR4 strain (23, 24) was measured using flow cytometry.
After incubation in human serum, there was wide variation in FH
binding between these strains, with over a 7.5-fold difference be-
tween the serotype with the highest binding to FH (serotype 2)
and the serotype with the lowest binding (serotype 11A) (Fig. 1A).
To assess whether these differences in FH binding affected strain
sensitivity to opsonization with complement, we measured the
deposition of the activated complement component C3b/iC3b
and the binding of Bf (as ameasure of alternative pathway activity)
for each strain. As previously shown by our group and others (2,
18), C3b/iC3b deposition showed major variations between cap-
sule-switched strains, with a 15-fold difference between the sero-
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type with the highest level of C3b/iC3b deposition (serotype 5)
and the serotype with the lowest level (serotype 2) (Fig. 1B). In
addition, Bf binding also varied significantly between capsule-
switched strains (Fig. 1C). To confirm differences in C3b/iC3b
deposition between capsule-switched strains identified by flow cy-
tometry and to locate sites of C3b/iC3b binding, immunogold EM
was performed on selected capsule-switched strains using an an-
tibody to C3b/iC3b. The total number of C3b/iC3b particles de-
tected were higher for the serotype 23F and 6A capsule-switched
strains than serotype 4 and 7F capsule-switched strains (Fig. 2A),
conforming to the pattern observed using a flow cytometry assay.
Although some C3b/iC3b was detected in the subcapsule region,
the majority of the differences in C3 binding between strains were
due to focal clusters of C3b/iC3b forming on the capsule (Fig. 2B
to E).
The level of FH binding to each capsular mutant showed a
strong negative correlation to both Bf binding and C3b/iC3b de-
position (Fig. 3A and B). FH binding did not correlate with cap-
sule thickness, the numbers of carbon atoms or presence of hy-
droxyl groups in the polysaccharide repeating unit for each
serotype (data not shown) (24). These results suggest that the
relative degree of FH binding between the capsule-switched
strains was functionally important, with high levels of FH binding
resulting in reduced alternative pathway activity and increased
resistance to opsonization with complement. As FH binding may
alter processing ofC3b bound to the bacterial surface to iC3b, flow
cytometry was used to assay specific iC3b deposition on selected
capsule-switched strains, two with high levels of FH binding and
two with low levels of FH binding (Fig. 3C). However, one of each
pair of strains had relatively high levels of iC3b deposition, with
the other having low levels, showing there was no consistent pat-
tern between FH and iC3b levels.
Effects of PspC on differences in FH binding and C3b/iC3b
deposition between selected capsule-switched strains. To fur-
ther assess the role of FH binding for differences in C3b/iC3b
deposition between capsule-switched strains, pspC was deleted
from the serotype 4 strain and two strains with relatively low levels
of FH binding, serotypes 6A and 23F. FH binding of all three pspC
mutant strains was markedly reduced, and in contrast to the data
for pspC parental strains, there were no differences in FH bind-
ing between the three pspC mutant strains (Fig. 4A and B). The
increase in C3b/iC3b deposition on the pspC serotype 6A and
23F strains compared to the serotype 4 strainwere reduced by 39%
and 71%, respectively, when the assay was repeated with the cor-
responding pspC mutants (Fig. 4C). These results demonstrate
FIG1 Flow cytometry data for the binding of complement factors to the TIGR4 capsule-switched strains. Data are presented as themean (SEM) FI of FHbinding
(A), C3b/iC3b deposition (B), and factor B binding (C).
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that differences in FH binding between capsule-switched strains
were PspC dependent andmade a significant contribution to vari-
ation in C3b/iC3b deposition results between serotypes.
Relationship of complement factor binding to capsule-
switched mutants and neutrophil association. Neutrophil
phagocytosis of S. pneumoniae is strongly dependent on comple-
ment activity (12, 25) and therefore should be affected by the
variation in opsonization with complement between capsule-
switched strains. After incubation in human serum, the propor-
tion of bacteria associated with human neutrophils (which is
strongly related to phagocytosis) (12, 25) varied significantly be-
tween capsule-switched strains from 19% (serotype 2) to 71%
(serotype 11A) (Fig. 5A). The degree of neutrophil association had
a strong negative correlation with FH binding (Fig. 5B) and a
strong positive correlation with C3b/iC3b deposition (Fig. 5C),
demonstrating that differences in complement factor binding be-
tween these strains were functionally important. To support the
flow cytometry data, neutrophil killing assays were performed for
selected capsule-switched strains, twowith high levels (5 and 11A)
and two with low (2 and 4) levels of neutrophil association. Neu-
trophil killing of the serotype 2 and 4 strains was very similar
under all conditions. In contrast, after opsonization with serum,
16% and 21%more of the serotype 5 and 11A strains were killed,
respectively, than the serotype 4 strain, falling to 8% for both
serotypes after opsonization in heat-treated serum or 6% and 7%
after incubation in PBS (Fig. 5D). These data confirmed that
strains with high levels of neutrophil association were more read-
ily killed by neutrophils and that this effect was largely dependent
on complement.
Role of antibody binding. Recognition by specific antibody
has a strong influence on complement activity against S. pneu-
moniae (26–28), and the serotype could potentially affect antibody
FIG 2 Immunogold EM of Cb/iC3b deposition on selected capsule-switched
strains. (A) Median (IQR) number of gold particles associated with transpar-
ent phase variants of serotype 4, 6A, 7F, and 23F capsule-switched strains on
ultrathin EM sections. P values for comparisons to serotype 4 data using the
Kruskal-Wallis test with Dunnett’s multiple comparisons are stated above the
corresponding column. (B to E) Representative EM pictures for the serotype
23F (B), 6A (C), 4 (D), and 7F (E) strains. Arrows indicate gold particles that
represent the location of C3b/iC3b deposition.
FIG 3 Spearman’s correlation of the FI for the FH binding results for the
capsule-switched variants to FI for Bf binding (A) and C3b/iC3b deposition
(B). (C) Flow cytometry data for specific iC3b deposition on selected capsule-
switched strains (serotypes 2, 4, 5, and 11A) presented as mean FIs with error
bars representing SEM.
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binding to S. pneumoniae through modifying access to subcapsu-
lar antigens or due to differences in levels of anticapsular antibody
between serotypes. Hence, total IgG binding (both to capsular and
subcapsular antigens) to each capsule-switched strain was mea-
sured using flow cytometry in the serum used for the complement
and phagocytosis experiments (Fig. 6A). Although there were sig-
nificant differences in total IgG binding between capsule-switched
strains, these were relatively small (with the exception of the sero-
type 4 strain) and did not positively correlate with C3b/iC3b de-
position (Fig. 6B). Furthermore, serum anticapsular antibody lev-
els (data available for 11 serotypes) also did not correlate with
C3b/iC3b deposition results (Fig. 6C).Hence, differences between
capsule-switched strains in their sensitivity to complement were
not related to differences in IgG binding.
Relationship of FH binding to serotype invasiveness.Wehy-
pothesized that serotypes resistant to complement due to high
levels of FH binding would be more likely to cause invasive dis-
ease. To investigate this, FH binding results for the capsule-
switched strains were correlated with invasiveness for the corre-
sponding serotypes represented by the attack rate calculated by
Sleeman et al. (Fig. 7A) (5). Serotypes 2 and 35B were excluded, as
there were no estimates of their invasiveness. Estimates of inva-
siveness are also not available for serotypes 1 and 5, as they are
found in cases of invasive disease but rarely as commensals, and
were assumed to have the highest attack rate identified among
other serotypes (assumed attack rate of 75) (5). FH binding posi-
tively correlatedwith attack rates (rs 0.62,P 0.0062), support-
ing the hypothesis that differences in FH binding could be influ-
encing serotype-dependent invasiveness. In addition, median FH
binding for 10 capsule-switched strains expressing highly invasive
serotypes (attack rates20) was higher than that for the 8 strains
expressing weakly invasive serotypes (attack rates10) (Fig. 5B).
Serotype 1 and 5 strains were clear outliers for these analyses with
low FH binding despite an assumed high attack rate (Fig. 7A);
their exclusion strengthened the correlation between FH binding
and the calculated serotype attack rates (rs 0.81,P 0.0001) and
increased differences in median FH between highly invasive and
weakly invasive serotypes (Fig. 7B). To strengthen the association
of FH binding with S. pneumoniae invasiveness, FH results were
correlated with the relative serotype invasiveness data described
FIG4 Role of PspC for FHbinding and differences inC3b/iC3b deposition between capsule-switched strains. (A) Flow cytometry data for FHbinding to selected
capsule-switched strains and their pspCmutant derivatives. Data are presented asmean FI for FHbinding, black columns represent pspC strains, white columns
represent pspCmutant strains, and gray columns represent pspC strains incubated in PBS (negative control). (B) Example of a flow cytometry histogram for FH
binding to serotype 4 pspC and pspCmutant strains. (C)Mean FI of C3b/iC3b deposition on the pspC and pspCmutant serotype 6A and 23F capsule-switched
strains expressed as a mean percentage of the results for the corresponding serotype 4 strain. Error bars represent SEM, and P values comparing pspC and pspC
mutant data in panels A and C were obtained by unpaired t tests.
Hyams et al.
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by Trotter (6) and Yildirim (8) independently of Sleeman (5).
With the Trotter data, median FH binding to highly invasive se-
rotype strains (pediatric disease case-to-carrier ratios of 100,
serotypes 7F, 9V, 14, and 18C) was higher than that for weakly
invasive serotype strains (case-to-carrier ratios of100; serotypes
3, 6A, 6B, 9N, 11A, 19A, 19F, 23F, and 35B) (Fig. 5C) and FH
binding showed a positive Spearman’s correlation with case-to-
carrier ratios (not shown) (rs 0.62, P 0.023) (6). The Yildirim
data for serotype invasiveness also showed a positive Spearman’s
correlation with FH binding, but only if the outlying serotype 35B
(which had high FH binding but was never found during invasive
disease) (8) was excluded (not shown) (rs 0.58, P 0.049).
PC analysis. To further assess the relationship between the
complement factor, neutrophil phagocytosis, and the attack rate
(5), a PC analysis was used to explore the relationships between
these measurements in a multivariate analysis. PC1, which in-
cluded a large positive loading for FH binding and a large negative
loading for C3b/iC3b deposition, variedmarkedly between strains
(Fig. 8A). PC1 also showed less negative loadings for the neutro-
phil association and Bf binding results (Fig. 8B). This supports the
hypothesis that these factors were cocorrelated and that the sero-
type has a common effect on FH binding, C3b/iC3b deposition,
and neutrophil phagocytosis. Importantly, PC1 results for each
capsule-switched strain had a strong correlation with the serotype
FIG 5 Complement-dependent neutrophil phagocytosis of capsule-switched variants. (A) Mean (SD) proportion of fresh human neutrophils associated with
each TIGR4 capsule-switched variants after opsonization with 20% serummeasured using flow cytometry. (B and C) Spearman’s correlation of the neutrophil
association results presented in panel A to the results for FH binding (B) or C3b/iC3b deposition (C) (both represented as FIs). (D) Neutrophil killing assay data
for selected capsule-switched strains (serotypes 2, 4, 5, and 11A). Data are presented as mean (SEM) proportion of the inoculum surviving after incubation with
human neutrophils for 1 h and given for bacteria preincubated in PBS and heat-treated and untreated 20% serum. Asterisks indicate strains with significant
differences to the serotype 4 strain (ANOVA with Dunnett’s post hoc comparisons; *, P 0.05, **, P 0.01).
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attack rate (rs 0.55, P 0.019 or rs 0.76, P 0.0007, exclud-
ing serotype 1 and 5 data). In this analysis, strains with high levels
of FH binding but low levels of C3b/iC3b deposition and neutro-
phil association expressed serotypes that epidemiological data
suggest are more likely to cause invasive infection (Fig. 8C).
FH binding by clinical S. pneumoniae isolates. To further
support the hypothesis that differences in FH binding might in-
fluence strain invasiveness, FH binding was analyzed using a set of
33 clinical isolates from 8 common serotypes with different ge-
netic backgrounds (19). FH binding varied significantly between
strains from different serotypes (e.g., serotype 1 strain versus se-
rotype 6A strain) and between strains expressing the same capsu-
lar serotype (e.g., serotype 4 and serotype 14) (Fig. 9A). To assess
if these differences could affect complement sensitivity binding,
the previously published C3b/iC3b deposition data for these
strains (19) were correlated with the FH binding results. FH bind-
FIG 6 Antibody binding to capsule-switched strains. (A) Mean (SD) FI of total IgG binding to TIGR4 capsule-switched variants measured by flow cytometry.
Levels (gml) of anticapsular serotype-specific IgGmeasured by ELISA are shown above each column (na, not available). (B and C) Spearman’s correlation of
total IgG (B) or anticapsular serotype-specific antibody levels (C) to FI of C3b/iC3b deposition on capsule-switched strains.
FIG 7 Relationship between FH binding to TIGR4 capsule-switched strains and S. pneumoniae serotype-related invasiveness. (A) Spearman’s correlation of FH
binding results for capsule-switched strains to the estimated attack rate for 18 serotypes (5). The outlier serotypes (serotype 1 and serotype 5) are marked,
excluding serotype 1 and 5 data (rs 0.81, P 0.0001). (B and C) Median (IQR) FH binding to capsule-switched mutants divided according to Sleeman et al.
(B) (5) or Trotter et al. (C) (6) into highly invasive (HI; attack rate20 or case-to-carrier ratios100) or weakly invasive (WI; attack rate10 or case-to-carrier
ratios 100) serotypes. P values are shown for Mann-Whitney U tests.
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ing was negatively correlated with C3b/iC3b deposition on the
clinical isolates (rs0.76, P 0.0001) (Fig. 9B), supporting the
hypothesis that variation in FHbinding has an important effect on
complement resistance for S. pneumoniae. Furthermore, although
there was considerable overlap between the groups, median FH
binding was higher on clinical strains from highly invasive capsu-
lar serotypes (1, 4, 9V, and 14) than strains from weakly invasive
capsular serotypes (6A, 6B, 19F, and 23F) (Fig. 9C).
DISCUSSION
There are surprisingly large variations in sensitivity to comple-
ment between S. pneumoniae strains (2, 3, 17–19). These differ-
ences partly depend on the capsular serotype (2, 3, 18), but the
mechanisms involved have not been identified. Using a large
number of capsule-switched strains in the TIGR4 background, we
have now shown that serotype-dependent differences in FH bind-
ing negatively correlated with differences in Bf binding, C3b/iC3b
deposition, and sensitivity to complement-dependent neutrophil
association. The flow cytometry data were supported by similar
results obtained using immunogold EM for selected strains. The
site of C3b/iC3b localization may also affect complement efficacy
at promoting phagocytosis, and the immunogold EM data sug-
gested that most of the increased C3b/iC3b deposition on some
serotypes was located on the capsule rather than at the cell wall
level where it may be a more effective opsonin (27). For the se-
lected capsule-switched strains investigated, FH binding was
largely dependent on the cell wall protein PspC, and loss of PspC
greatly reduced differences in C3b/iC3b deposition between
strains. These results support the hypothesis that the effects of the
serotype on FH binding to the subcapsular protein PspC could be
one mechanism causing differences in complement sensitivity
binding between different S. pneumoniae capsular serotypes. The
thickness of the capsule layer varies between the TIGR4 capsule-
switched strains used for these studies (24), but neither this nor
the numbers of carbon atoms or the presence of hydroxyl groups
correlated with the FH binding results, and how the serotype af-
fects FH binding will need further investigation. Of note, minor
changes may have large effects; for example, serotypes 19A and
19F differ in structure by a single bond in the trisaccharide repeat-
ing unit (1) yet have significant differences in FH binding and
complement sensitivity.
Neutrophil phagocytosis is thought to be a major mechanism
of bacterial killing of S. pneumoniae and is highly dependent on
intact complement activity (12, 22, 29). The negative correlation
between FH binding and neutrophil phagocytosis of serum op-
sonized S. pneumoniae (supported by the neutrophil killing assay
for selected strains) confirms that the differences in FH binding
and C3b/iC3b deposition between capsule-switched strains is
functionally relevant. In addition, variations in FH binding be-
tween clinical isolates negatively correlated with C3b/iC3b depo-
sition, demonstrating that FHbinding could also be important for
variations in complement sensitivity between clinical isolates as
well as the capsule-switched strains. FH binding varied between
strains expressing the same capsular serotypes, indicating that
capsule-independent mechanisms such as differences in PspC ex-
pression or allelic variation in PspC structure (30) may also affect
FH interactions with S. pneumoniae.
The essential role for complement to protect against systemic
infection caused by S. pneumoniae (14–16) suggests that varia-
tions in complement sensitivity between strains should affect in-
vasiveness. In support of this hypothesis, we found a positive re-
lationship between FH binding to the capsule-switched strains
and different sets of epidemiological data on invasiveness of each
serotype. Furthermore, the PC analysis demonstrated that cap-
sule-switched strains expressing weakly invasive serotypes had
low levels of FH binding, relatively high levels of factor B and
C3b/iC3b binding, and high levels of neutrophil association.
Overall, our data suggest that the degree of binding to FH could be
a critical factor in explaining some of the variation in invasiveness
between S. pneumoniae strains. By binding high levels of FH, in-
vasive S. pneumoniae serotypes are relatively resistant to comple-
ment-dependent neutrophil phagocytosis, so they can evade com-
plement-mediated systemic immunity, and this may make them
more likely to cause septicemia. Differences in FH binding be-
tween serotype were dependent on PspC, and the capsular sero-
type could potentially also affect other functions of PspC. These
include bacterial adhesion to and invasion across epithelial layers
(31, 32), which could provide another explanation of why high
levels of FH binding positively correlate with serotype invasive-
ness independent of the effects on complement activity. Interest-
ingly, the neutrophil association of serum-opsonized capsule-
switched strains gave a different serotype rank order for resistance
to phagocytosis compared to complement-independent neutro-
phil phagocytosis obtained using the same set of capsule-switched
FIG 8 PC analysis of FH, Bf, C3b/iC3b, and neutrophil opsonophagocytosis
data for the TIGR4 capsule-switched strains. (A) Relative variance of each PC.
(B) Contribution of each variable to the variance between strains in PC1. (C)
The correlation between variance of PC1 with serotype invasiveness repre-
sented by the attack rate (5).Data points represent individual serotypes and the
linear regression is shown for the relationship between the attack rate and PC1.
Spearman’s rs and P values are given for data, excluding the serotype 1 and
serotype 5 strains.
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strains (24). Hence, the effects of each serotype on interactions
with the host may depend on opsonizing conditions.
With the correlations between complement factor binding and
serotype invasiveness, the capsule-switched serotype 1 and 5
strains were significant outliers with relatively low FH binding but
an assumed high invasiveness. As a consequence, although FH
binding positively correlated with invasiveness when these strains
were included in the analyses, the strength of the association im-
proved markedly when they were excluded. S. pneumoniae sero-
types have markedly different biological and genetic characteris-
tics, and it is perhaps not surprising that some serotypes did not
conform to the general pattern. Serotype 1 is the only capsular
serotype that is zwitterionic, and both serotypes 1 and 5 have
unusual epidemiological characteristics. They have a relatively flat
age-incidence pattern and are rarely found in the nasopharyngeal
carriage (5, 7); as a consequence of the latter, invasiveness has not
been calculated for these serotypes and, for our analysis, an as-
sumed attack rate of 75 had to be used, whichmay not be accurate.
The biological reasons for the differences in the epidemiology of
serotype 1 and serotype 5 strainsmay also account forwhy they are
highly invasive independent of their complement sensitivity phe-
notype.
Although we have shown strong correlations between FH
binding, complement resistance, and serotype invasiveness, it is
difficult to prove that differences in FHbinding cause variations in
invasiveness. Demonstrating that differences between capsule-
switched strains in complement sensitivity and invasiveness are
abrogated in the absence of FH would provide strong support for
this hypothesis. However, FH knockout mice are functionally C3
deficient due to uncontrolled complement activity. Furthermore,
comparing virulence between capsule-switched stains using
mouse models may be difficult to interpret; the S. pneumoniae
strain background has unpredictable effects in mouse infection
models, and TIGR4 capsule-switched strains expressing serotype
6A, 23F, and 7F did not cause significant disease in some models
(4). Alternatively, experiments could be repeated using pspCmu-
tant strains. However, the deletion of pspC increases the quantity
of cell-associated PspA (J. S. Brown, unpublished data), another
choline-binding protein that affects complement activity (16, 33).
This will confound the interpretation of results obtained using
pspCmutants and perhaps explains why there has been a variable
effect of the deletion of pspC on complement sensitivity between
strains (22). Instead, we have sought additional support for the
hypothesis by comparing median FH binding to clinical strains
when divided by serotype into highly or weakly invasive groups.
Invasive potential varies between strains with the same capsular
serotype, which will partially confound these comparisons (34).
Despite this, there was still a significantly higher level of FH bind-
ing to clinical isolates expressing more invasive serotypes.
In conclusion, we have shown that the capsular serotype has
significant effects on FH binding by S. pneumoniae and that sero-
types with high levels of FH binding were resistant to comple-
ment-mediated immunity and are associated with increased inva-
siveness. The data suggest that the capsule does not simply aid
virulence by blocking bacterial interactions with host proteins.
Instead, more invasive capsular serotypes tend to have increased
binding to a specific host protein (FH), and this is one plausible
mechanism that might explain their increased invasiveness com-
pared to other strains. How capsular serotype can cause variations
FIG 9 FH binding to representative clinical isolates for common serotypes. (A) Mean (SD) FI of FH binding to 33 clinical strains from 8 serotypes measured
using flow cytometry. The P value was obtained using ANOVA. (B) Spearman’s correlation of C3b/iC3b deposition (log10 FI; previously published data) (19) to
the results of FH binding to the clinical isolates. (C) Median (IQR) FH binding to the clinical strains divided into highly invasive (HI; attack rate20; serotypes
1, 4, 9V, and 14) and weakly invasive (WI; attack rate10; serotypes 6A, 6B, 19F, and 23F) serotypes (5). The P value was calculated using the Mann-Whitney
U test.
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in FH binding and how this could affect invasiveness will need
further investigation.
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